Shengtai Pharmaceutical Retains DME Capital LLC to Implement Global Investor Relations Program

WEIFANG, Shandong, China, Aug. 11 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical (OTC Bulletin Board: SGTI), announced today that it has retained DME Capital LLC, a New York-based Investor Relations firm, to expand the Company's strategic investor relations program.

Mr. Qingtai Liu CEO of Shengtai Pharmaceutical stated, "As we continue to grow our operations, we believe this is the right time to send our message to the investment community. After careful consideration, DME Capital, with their established relationships among institutional investors, combined with their extensive databases and pro active investor relations program, is the perfect partner for Shengtai Pharmaceutical."

About DME Capital LLC

DME Capital LLC is a full service investor relations firm, representing growth oriented companies to the investment community. Investor Relations services include financial community and media relations, editorial services and interactive communications, as well as administrative, consulting and advisory services. DME Capital LLC ensures money, fund, and portfolio managers, financial analysts, brokers and individual investors receive a constant flow of information and updates. To learn more about DME Capital LLC go to http://www.dmecapital.com .

About Shengtai Pharmaceutical:

Shengtai Pharmaceutical founded in 1999 is a leading domestic producer of pharmaceutical-grade glucose in China. The company has about 40% of the market and one of the only three licensed Dextrose Monohydrate manufacturers in China. With increased production capacity ready, the company will have potential to acquire 50% of China's pharmaceutical glucose market in about 1-2 years. The Company has had great growth revenue in the past several years. The company's products include pharmaceutical-grade glucose or dextrose, used for medical purposes as well as other glucose and cornstarch products used for the food and beverage industry, and for industrial productions in China. The company's main customers include medical supply companies, pharmaceutical companies, medical supply exporters, and food and beverage companies covering all of China with the exception of Tibet. The Company also exports its products to more than 70 different countries.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

    For more information, please contact:

     Shengtai Pharmaceutical, Inc.
     Tel:   +86-536-629-5802
     Email: [email protected]

     Investor Relations:
     DME Capital LLC
     Steven Marcus
     Tel:   +1-917-648-0663

SOURCE Shengtai Pharmaceutical, Inc.